(Q54185800)

English

Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

prostate carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

9

object named as

Y Hasegawa

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

author name string

S Naito

1

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

T Ueda

2

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

S Kotoh

3

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

J Kumazawa

4

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

K Itoh

5

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

K Sagiyama

6

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

T Omoto

7

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

S Andoh

8

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

Y Fujisawa

10

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

publication date

1 January 1995

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

35

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

3

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

225-229

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

https://scigraph.springernature.com/pub.10.1007/bf00686552

0 references

Treatment of estrogen-resistant stage D carcinoma of prostate with cis diamminedichloroplatinum

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of etoposide for carcinoma of the prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor spectrum of a new anthracycline, (2"R)-4'-O-tetrahydropyranyladriamycin, and effect on the cellular immune response in mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II clinical study of pirarubicin in hormone resistant prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Establishment of cross-resistance profiles for new agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response criteria for the prostate of the USA national prostatic cancer project

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Small-cell carcinoma of prostate. Transient complete remission with chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum II

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II).

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoposide--chemistry, preclinical and clinical pharmacology

1 reference

https://pubmed.ncbi.nlm.nih.gov/7805181

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00686552

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/7805181

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54185800&oldid=1582950069"